Financial Data and Key Metrics Changes - For the year ended December 31, 2024, the company recorded revenues of $43.3 million, an increase from $31.6 million in 2023, representing a growth of $11.7 million largely due to collaboration arrangements for siRNA platform development [20][21] - The company's net operating loss for 2024 was approximately $63.3 million, a slight decrease from $64.4 million in 2023, attributed to increased revenue offset by rising R&D costs [26] - The net loss for 2024 was approximately $45.3 million compared to $54.2 million in 2023, with cash, cash equivalents, and short-term investments totaling $147.3 million at the end of December 2024 [27] Business Line Data and Key Metrics Changes - The Phase 2 study of zerlasiran showed positive results with Lp(a) reductions exceeding 90%, supporting a competitive profile for further development in Phase 3 [5][6] - Divesiran's Phase 1 study results indicated it completely eliminated the need for phlebotomy in well-controlled patients, with a favorable safety profile [8][14] - The company plans to prioritize investment in programs targeting rare conditions, with divesiran for polycythemia vera (PV) remaining a top priority [10][29] Market Data and Key Metrics Changes - The company has received Orphan Drug Designation for divesiran from the European Commission, and it also holds FDA Fast Track and Orphan Drug Designations for PV [8] - The market opportunity for treating high Lp(a) is significant, with few cardiovascular assets targeting this unmet medical condition [12] Company Strategy and Development Direction - The company will only initiate the Phase 3 outcomes study for zerlasiran once a partner is secured, extending its cash runway into 2027 [28][53] - The focus will be on advancing innovative siRNA therapies for rare conditions, with a commitment to delivering life-changing treatments [29][56] - The company is evaluating multiple undisclosed programs from its GOLD platform for potential development or partnership [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of zerlasiran and divesiran, highlighting the positive feedback received from global regulatory agencies regarding the Phase 3 program design for zerlasiran [6][12] - The company is actively engaged in partnership discussions for zerlasiran, with a focus on securing the right partner for development and commercialization [61] Other Important Information - Silence has transitioned to a U.S. domestic issuer effective January 1, 2025, requiring compliance with U.S. GAAP and SEC reporting [19] - The company plans to start a Phase 1 study of SLN548, targeting complement factor B, in the second half of the year [50] Q&A Session Summary Question: Can you provide some color on partnership discussions for zerlasiran? - Management did not comment specifically on ongoing partnership discussions but noted increased funding for Lp(a) studies from companies like Novartis [59][61] Question: How ready is the company for the Phase 3 trial of zerlasiran? - The company is wrapping up Phase 3 readiness activities and is on track to complete them by mid-year, allowing for some adjustments with a partner [67] Question: What is the goal for divesiran regarding differentiation? - The goal is to be the first siRNA to market for PV, with a focus on infrequent dosing and symptomatic improvement as key differentiators [75][78] Question: What are the biggest hurdles for partnering zerlasiran? - Hurdles vary by party, but discussions often revolve around business strategy and the recognition of the large market opportunity [79][80] Question: What is the status of the candidates developed for Hansoh? - The company is interested in the programs developed under the partnership and will evaluate the opportunity to develop them independently or through partnerships [84]

Clinical Trial Updates - ALPACAR-360 Phase 2 study of Zerlasiran delivered positive results in high Lp(a)[9, 10] - SANRECO Phase 1 study of Divesiran delivered positive results in PV and was granted orphan drug designation for PV in EU[9, 10] - SANRECO Phase 2 study of Divesiran dosed first PV patient, with full enrollment anticipated by year-end 2025[10, 12, 48] - SLN548 (complement factor B) Phase 1 study start anticipated in 2H 2025[12, 48] Divesiran in Polycythemia Vera (PV) - Divesiran is a first-in-class siRNA for PV with FDA Fast Track and Orphan Drug Designations[26, 27] - Phase 1 study showed Divesiran reduced phlebotomy frequency in PV patients who had 79 phlebotomies prior to dosing, but only 5 in the treatment period and 2 in follow-up[29, 31] - Divesiran decreased hematocrit in all cohorts in Phase 1 study[32, 34] - Divesiran treatment produced sustained increases in Hepcidin[36, 38] - Divesiran demonstrated a favorable safety and tolerability profile, with 84% of treatment emergent adverse events (TEAEs) being grade 1[40, 41] Financial Performance and Guidance - Revenue for FY 2024 was $43258 thousand, compared to $31634 thousand in FY 2023[16] - Net loss for FY 2024 was $45309 thousand, compared to $54228 thousand in FY 2023[16] - Cash position at the end of December 2024 was $147334 thousand, including $121300 thousand in cash and cash equivalents and $26000 thousand in short-term investments[16, 17] - Projected cash runway extended into 2027[18]

Part I [Business](index=7&type=section&id=Item%201.%20Business) Silence Therapeutics develops siRNA therapeutics using its mRNAi GOLD™ platform, focusing on cardiovascular, hematology, and rare diseases through its pipeline and collaborations - The company focuses on discovering and developing siRNA molecules to inhibit specific target genes using its proprietary **mRNAi GOLD™ platform**[23](index=23&type=chunk) - The wholly-owned pipeline is concentrated in three therapeutic areas: **cardiovascular disease, hematology, and rare diseases**[23](index=23&type=chunk) [Our Pipeline](index=8&type=section&id=Our%20Pipeline) The company advances siRNA programs from its mRNAi GOLD™ platform, including clinical-stage Divesiran for PV and Zerlasiran for cardiovascular disease, and a Phase 1 candidate with AstraZeneca - **Divesiran (SLN124)**, a wholly-owned siRNA candidate for polycythemia vera (PV), is in a Phase 2 clinical trial (SANRECO) and has received Fast Track and orphan drug designations from the FDA and Europe[24](index=24&type=chunk) - **Zerlasiran (SLN360)**, a wholly-owned siRNA candidate to lower lipoprotein(a) (Lp(a)), completed Phase 1 and 2 trials showing substantial Lp(a) reduction, and the company is seeking a partner for Phase 3 development[25](index=25&type=chunk)[26](index=26&type=chunk) - A third product candidate, developed with AstraZeneca, is in Phase 1 development for an undisclosed indication[27](index=27&type=chunk) [Collaborations](index=16&type=section&id=Collaborations) The company maintains strategic collaborations, including a Phase 1 program with AstraZeneca, while partnerships with Mallinckrodt and Hansoh have concluded, with Silence retaining rights for Hansoh targets - The AstraZeneca collaboration covers up to 10 targets, with **$60 million in upfront and unconditional payments**, a **$20 million equity investment**, and a **$10 million milestone payment** triggered by Phase 1 trial initiation, with potential for up to **$390 million per target** in milestones plus royalties[65](index=65&type=chunk)[66](index=66&type=chunk) - The Mallinckrodt collaboration concluded in March 2024 after Mallinckrodt decided not to pursue further development of SLN501, with Silence having reacquired rights to two other preclinical complement targets in March 2023[67](index=67&type=chunk)[68](index=68&type=chunk) - The Hansoh collaboration concluded in December 2024, with Silence retaining exclusive global rights for all three original targets[70](index=70&type=chunk) [Intellectual Property](index=17&type=section&id=Intellectual%20Property) The company protects its siRNA platform and product candidates through patents and trade secrets, holding 62 solely owned granted patents and 150 pending applications as of December 31, 2024 Patent Portfolio as of December 31, 2024 | Category | Count | | :--- | :--- | | **Solely Owned Granted Patents** | 62 (221 including EU validations) | | - U.S. Issued Patents | 14 | | **Pending Patent Applications** | 150 (138 solely owned) | | - U.S. Pending Applications | 11 (10 solely owned) | - Patent families covering the siRNA chemistry toolbox elements, if granted, are expected to expire no earlier than **2036**[84](index=84&type=chunk) - Patent families covering the siRNA sequences for product candidates **SLN360** and **SLN124**, if granted, are expected to expire no earlier than **2038**[84](index=84&type=chunk) [Government Regulation and Product Approval](index=19&type=section&id=Government%20Regulation%20and%20Product%20Approval) The company navigates extensive government regulations for drug approval in the US (FDA), EU (EMA), and UK (MHRA), covering preclinical, clinical, manufacturing, and post-market requirements, with an evolving regulatory landscape - The U.S. drug approval process involves preclinical studies, an effective IND, IRB-approved clinical trials (Phase 1, 2, 3), and NDA submission to the FDA[86](index=86&type=chunk) - In the EU, clinical trials are governed by the Clinical Trials Regulation (CTR), streamlining application and assessment through a centralized EU portal[132](index=132&type=chunk) - The UK has its own post-Brexit regulatory framework managed by the MHRA, including national authorization procedures and the International Recognition Procedure (IRP) leveraging other trusted regulators' approvals[157](index=157&type=chunk)[158](index=158&type=chunk) [Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including historical net losses, capital needs, inherent drug development uncertainties, reliance on third parties, intense competition, intellectual property challenges, and increased compliance costs from its U.S. domestic issuer transition - The company has a history of net losses, with a **net loss of $45.3 million in 2024** and an accumulated loss of **$474.0 million** as of December 31, 2024, anticipating continued significant losses[173](index=173&type=chunk) - The company's novel siRNA technology may not lead to marketable products, and its focus on a single technology platform increases inherent development risk[190](index=190&type=chunk)[192](index=192&type=chunk) - Reliance on third parties for manufacturing (CMOs) and clinical research (CROs) introduces risks related to performance, quality, and supply chain disruptions[210](index=210&type=chunk)[213](index=213&type=chunk) - Effective January 1, 2025, the company transitioned to a 'U.S. domestic issuer', resulting in increased compliance costs and reporting requirements under SEC rules[304](index=304&type=chunk) [Cybersecurity](index=74&type=section&id=Item%201C.%20Cybersecurity) The company manages cybersecurity risks through an information security program overseen by its audit and risk committee, employing threat identification, mitigation measures, and third-party vendor risk management - The company's cybersecurity risk management is overseen by the board's audit and risk committee and managed by the Head of IT[368](index=368&type=chunk)[369](index=369&type=chunk) - The security strategy includes incident detection and response, vulnerability management, disaster recovery, risk assessments, encryption, and employee training[363](index=363&type=chunk) - The company relies on third-party service providers for various functions and manages associated cybersecurity risks through vendor assessments and contractual requirements[366](index=366&type=chunk) [Properties](index=75&type=section&id=Item%202.%20Properties) The company leases all its facilities, including corporate headquarters in London, UK, and office/laboratory spaces in Berlin, Germany, and Hoboken, New Jersey, which are deemed adequate for near-term needs - The company leases office and lab space in London (UK), Berlin (Germany), and Hoboken (NJ, USA)[373](index=373&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities](index=76&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%2C%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's ADSs trade on Nasdaq under 'SLN' since September 2020, with no dividends paid or intended, as earnings are retained for business development - The company's ADSs (ticker: **SLN**) began trading on Nasdaq in **September 2020**, with each ADS representing three ordinary shares[378](index=378&type=chunk) - The company has never declared or paid dividends and does not intend to in the foreseeable future, retaining earnings for business growth[380](index=380&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=78&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) For 2024, the company reported **$43.3 million in revenue** and a **net loss of $45.3 million**, with R&D expenses increasing to **$67.9 million**, and ended the year with **$147.3 million in cash** after significant capital raises [Results of Operations](index=86&type=section&id=Results%20of%20Operations) For 2024, revenue increased to **$43.3 million** due to the Hansoh collaboration, while R&D expenses rose to **$67.9 million**, resulting in an improved net loss of **$45.3 million** Consolidated Results of Operations (in thousands) | | 2024 | 2023 | 2022 | | :--- | :--- | :--- | :--- | | **Revenue** | **$43,258** | **$31,643** | **$21,655** | | Gross profit | 31,448 | 18,776 | 8,192 | | Research and development costs | (67,883) | (56,937) | (43,550) | | General and administrative expenses | (26,884) | (26,222) | (25,682) | | Operating loss | (63,319) | (64,383) | (61,040) | | **Net Loss** | **$(45,309)** | **$(54,228)** | **$(50,334)** | | Loss per share (basic and diluted) | $(0.33) | $(0.49) | $(0.52) | - Revenue increased to **$43.3 million** in 2024 from **$31.6 million** in 2023, primarily due to recognizing **$24.6 million** from the Hansoh Collaboration upon its conclusion[430](index=430&type=chunk) - Research and development expenses increased by **$11.0 million** year-over-year to **$67.9 million** in 2024, driven by additional clinical trials and increased contract manufacturing for proprietary programs[436](index=436&type=chunk) [Liquidity and Capital Resources](index=88&type=section&id=Liquidity%20and%20Capital%20Resources) As of December 31, 2024, the company held **$147.3 million** in cash and investments, bolstered by **$120.0 million** from a private placement and **$27.7 million** from ATM sales, with net cash outflow from operations at **$67.6 million** - As of December 31, 2024, the company had cash, cash equivalents, and short-term investments of **$147.3 million**[443](index=443&type=chunk) - In February 2024, the company raised approximately **$120.0 million** in gross proceeds through a private placement of ADSs[445](index=445&type=chunk) - In 2024, the company raised **$27.7 million** in proceeds (before fees) from sales of ADSs under its Open Market Sale Agreement (ATM facility)[444](index=444&type=chunk) Summary of Cash Flows (in thousands) | | 2024 | 2023 | 2022 | | :--- | :--- | :--- | :--- | | Net cash outflow from operating activities | $(67,640) | $(49,462) | $(57,044) | | Net cash (outflow)/inflow from investing activities | $(21,966) | $19,294 | $(20,498) | | Net cash inflow from financing activities | $142,087 | $31,937 | $52,581 | [Controls and Procedures](index=96&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2024, with PricewaterhouseCoopers LLP issuing an unqualified opinion on internal controls - Management concluded that the company's disclosure controls and procedures were effective as of **December 31, 2024**[489](index=489&type=chunk) - Management assessed internal control over financial reporting as effective as of **December 31, 2024**, based on the COSO framework[492](index=492&type=chunk) - The independent registered public accounting firm, PricewaterhouseCoopers LLP, issued an unqualified opinion on the effectiveness of the company's internal control over financial reporting as of **December 31, 2024**[494](index=494&type=chunk) Part III Information for Items 10 through 14, covering Directors, Executive Officers, Corporate Governance, Executive Compensation, Security Ownership, and Related Transactions, is incorporated by reference from the company's 2025 Proxy Statement [Directors, Executive Officers and Corporate Governance](index=98&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information for this item is incorporated by reference from the company's 2025 Proxy Statement, which also details the adopted Code of Business Conduct and Ethics and Insider Trading Policy - Information for this item is incorporated by reference from the Proxy Statement for the **2025 Annual General Meeting of Shareholders**[500](index=500&type=chunk) [Executive Compensation](index=98&type=section&id=Item%2011.%20Executive%20Compensation) Information regarding executive compensation is incorporated by reference from the company's 2025 Proxy Statement - Information for this item is incorporated by reference from the Proxy Statement for the **2025 Annual General Meeting of Shareholders**[503](index=503&type=chunk) Part IV [Exhibits and Financial Statement Schedules](index=99&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists the financial statements and exhibits filed as part of the Annual Report on Form 10-K, including auditor reports, consolidated financial statements, and various corporate governance documents Financial Statements [Report of Independent Registered Public Accounting Firm](index=103&type=section&id=Report%20of%20Independent%20Registered%20Public%20Accounting%20Firm) PricewaterhouseCoopers LLP issued an unqualified opinion on the consolidated financial statements and internal control over financial reporting, identifying R&D accruals as a Critical Audit Matter - The auditor, PricewaterhouseCoopers LLP, issued an unqualified (clean) opinion on both the consolidated financial statements and the effectiveness of internal control over financial reporting[525](index=525&type=chunk) - A Critical Audit Matter (CAM) was identified concerning the accuracy of management's assessment of accruals and prepayments for third-party research and development contracts, due to the significant judgment required to estimate the stage of completion[533](index=533&type=chunk)[534](index=534&type=chunk) [Consolidated Financial Statements](index=105&type=section&id=Consolidated%20Financial%20Statements) The consolidated financial statements show total assets of **$202.6 million** and total liabilities of **$68.6 million** as of December 31, 2024, with a **net loss of $45.3 million** on **$43.3 million in revenue** for the year Consolidated Balance Sheet Data (in thousands) | | Dec 31, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $121,330 | $68,789 | | Total current assets | $187,366 | $103,151 | | **Total assets** | **$202,635** | **$119,448** | | Total current liabilities | $(16,822) | $(22,336) | | **Total liabilities** | **$(68,612)** | **$(97,455)** | | **Total shareholders' equity** | **$(134,023)** | **$(21,993)** | Consolidated Income Statement Data (in thousands) | | Year ended Dec 31, 2024 | Year ended Dec 31, 2023 | Year ended Dec 31, 2022 | | :--- | :--- | :--- | :--- | | Revenue | $43,258 | $31,643 | $21,655 | | Operating loss | $(63,319) | $(64,383) | $(61,040) | | **Net Loss** | **$(45,309)** | **$(54,228)** | **$(50,334)** | [Notes to the Consolidated Financial Statements](index=110&type=section&id=Notes%20to%20the%20Consolidated%20Financial%20Statements) The notes detail accounting policies, including U.S. GAAP transition and revenue recognition, with significant 2024 contributions from AstraZeneca and Hansoh collaborations, and provide insights into equity changes and share-based compensation expenses - The company transitioned from IFRS to U.S. GAAP, applied retrospectively, due to the loss of its 'foreign private issuer' status[551](index=551&type=chunk) - Revenue from collaboration agreements is recognized over time using a cost-to-cost input method, as the license and R&D services are considered a single performance obligation per target[568](index=568&type=chunk) - In 2024, the company raised gross proceeds of **$120.0 million** from a private placement and **$27.7 million** from its ATM sales agreement[657](index=657&type=chunk)[658](index=658&type=chunk) - Share-based compensation expense for 2024 was **$16.3 million**, with **$29.1 million** of total unrecognized compensation cost related to unvested stock options as of year-end[665](index=665&type=chunk)[667](index=667&type=chunk)

[Full Year 2024 Financial Results and Business Update](index=1&type=section&id=Full%20Year%202024%20Financial%20Results%20and%20Business%20Update) [Business Highlights](index=1&type=section&id=Business%20Highlights) The company advanced its mRNAi GOLD™ platform with strong clinical execution, prioritizing rare disease programs and extending its cash runway into 2027 by partnering zerlasiran - The company is strategically prioritizing investments in programs for rare conditions, such as **divesiran for Polycythemia Vera (PV)**[2](index=2&type=chunk) - The Phase 3 cardiovascular outcomes study for zerlasiran will only be initiated after securing a partner, a decision that **extends the company's cash runway into 2027**[2](index=2&type=chunk)[6](index=6&type=chunk) [Zerlasiran for Cardiovascular Disease](index=1&type=section&id=Zerlasiran%20for%20Cardiovascular%20Disease) The zerlasiran program received positive regulatory feedback for its Phase 3 design and is prepared for H1 2025, with initiation contingent on securing a partnership - Received **positive feedback on the Phase 3 study design** from major global regulatory bodies including the U.S. FDA, European EMA, and Japanese PMDA[4](index=4&type=chunk) - The program is on track to be **Phase 3 ready in H1 2025**, but the study's start is dependent on securing a partner[4](index=4&type=chunk) [Divesiran for Polycythemia Vera (PV)](index=1&type=section&id=Divesiran%20for%20Polycythemia%20Vera%20(PV)) The divesiran program is advancing with Phase 1 follow-up concluded and Phase 2 enrollment expected to complete by year-end 2025 - Follow-up has concluded in the SANRECO Phase 1 study, with **data presentations anticipated in 2025**[4](index=4&type=chunk) - **Full enrollment in the SANRECO Phase 2 study** is expected by the end of 2025[2](index=2&type=chunk)[4](index=4&type=chunk) [Other mRNAi GOLD™ Pipeline Updates](index=1&type=section&id=Other%20mRNAi%20GOLD%E2%84%A2%20Pipeline%20Updates) The company plans a Phase 1 study for SLN548, continues the SLN312 study, and has regained rights to three preclinical programs from Hansoh Pharma - A Phase 1 study of **SLN548**, a wholly-owned siRNA candidate for complement-mediated diseases, is planned for **H2 2025**[3](index=3&type=chunk) - The collaboration with Hansoh Pharma has ended, and **Silence has regained global rights** to all three associated preclinical programs[9](index=9&type=chunk) - A Phase 1 study of **SLN312**, which is licensed to AstraZeneca, is currently ongoing[9](index=9&type=chunk) [Financial Highlights and Guidance](index=2&type=section&id=Financial%20Highlights%20and%20Guidance) The company reported a strong cash position of $147.3 million, increased collaboration revenue, a narrowed net loss, and an extended cash runway into 2027 Key Financial Metrics for Year End 2024 | Metric | 2024 | 2023 | | :--- | :--- | :--- | | Cash, Cash Equivalents, and Short-term Investments | $147.3 million | $68.8 million | | Collaboration Revenue | $43.1 million | $30.9 million | | R&D Expenses | $67.9 million | $56.9 million | | G&A Expenses | $26.9 million | $26.2 million | | Net Loss | $45.3 million | $54.2 million | | Net Loss Per Share | $0.33 | $0.49 | - The company's projected **cash runway is now extended into 2027**[2](index=2&type=chunk)[6](index=6&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) The 2024 consolidated financial statements show increased revenue, a reduced net loss, and a significantly strengthened balance sheet with higher cash and lower liabilities [Consolidated Statements of Income (Loss)](index=5&type=section&id=Consolidated%20Statements%20of%20Income%20(Loss)) For fiscal year 2024, revenue increased to $43.3 million while the net loss improved to $45.3 million, or $0.33 per share Consolidated Statements of Income (Loss) (in thousands, except for loss per share) | | 2024 | 2023 | | :--- | :--- | :--- | | **Revenue** | **$ 43,258** | **$ 31,643** | | Gross profit | $ 31,448 | $ 18,776 | | Research and development costs | $ (67,883) | $ (56,937) | | General and administrative expenses | $ (26,884) | $ (26,222) | | Operating loss | $ (63,319) | $ (64,383) | | **Net Loss** | **$ (45,309)** | **$ (54,228)** | | **Loss per share (basic and diluted)** | **$ (0.33)** | **$ (0.49)** | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) As of December 31, 2024, the balance sheet reflects strong liquidity with total assets of $202.6 million and significantly reduced total liabilities Consolidated Balance Sheets (in thousands) | | Dec 31, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | **Current assets** | | | | Cash and cash equivalents | $ 121,330 | $ 68,789 | | Short-term investments | $ 26,004 | $ — | | **Total current assets** | **$ 187,366** | **$ 103,151** | | **Total assets** | **$ 202,635** | **$ 119,448** | | **Current liabilities** | | | | Total current liabilities | $ (16,822) | $ (22,336) | | **Total liabilities** | **$ (68,612)** | **$ (97,455)** | | **Total shareholders' equity** | **$ (134,023)** | **$ (21,993)** |

Shares of Silence Therapeutics (SLN) plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) or Lp(a), a key genetic risk factor for cardiovascular disease. The stock price drop is likely due to investors’ skepticism regarding the effectiveness of the candidate compared to other treatments being developed for the same indication.The results from th ...

On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).These data were presented at the American Heart Association (AHA) Scientific Sessions.Results showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in ...

Exhibit 99.1 Condensed consolidated income statement (unaudited) | --- | --- | --- | --- | --- | |---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------| | £000s (except per share information) | Three months ended \nSeptember 30, 2024 \n£000s | Three months ended \nS ...

Pathompong Thongsan/iStock via Getty Images Silence Therapeutics plc (NASDAQ:SLN) develops RNA interference ("RNAI") therapies that silence genes associated with various diseases. SLN employs its proprietary mRNAi GOLD platform to produce short interfering RNAs (siRNAs) that degrade disease-related mRNA. It focuses especially on genes expressed in the liver, which is an ideal target due to its essential role in metabolism and regulating proteins, fats, and carbohydrates. Currently, SLNCF's main drug candida ...

andresr/E+ via Getty Images The last time I wrote about Silence Therapeutics plc (NASDAQ:SLN) it was in a Seeking Alpha article entitled "Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results." With this article, I noted that the company had already released positive results using one of its small interfering RNA [siRNA] candidates, known as zerlasiran. This is for the treatment of patients with elevated levels of Lp[a] at high risk of atherosclerotic cardiovascular disease [ASCVD]. ...

Exhibit 99.1 Condensed consolidated income statement (unaudited) | --- | --- | --- | --- | --- | |---------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|------------------------------------------------------|--------------------------------------------------| | £000s (except per share information) | Three months ended \nJune 30, 2024 \n£000s | Three months ended \nJune 30, 2023 \n£000s | Six ...